Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Phase I Trial to Evaluate the Immunomodulatory Effect of RUTI in Individuals With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Treated With Intravesical Bacillus Calmette-Guerin (BCG)

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase I Trial to Evaluate the Immunomodulatory Effect of RUTI in Individuals With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Treated With Intravesical Bacillus Calmette-Guerin (BCG)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs Tuberculosis vaccine (Primary)
  • Indications Tuberculosis
  • Focus Pharmacodynamics
  • Acronyms RUTIVAC-1
  • Sponsors Archivel Farma
  • Most Recent Events

    • 09 Jan 2019 Status changed from suspended to recruiting.
    • 31 Aug 2018 Biomarkers information updated
    • 29 Aug 2018 Planned End Date changed from 31 Aug 2019 to 31 Mar 2024.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top